Epidemiological and pathogen characteristics of symptomatic male reproductive tract infections in Hunan province: retrospective study Authors: Xiaobing Xie, Senmiao Zhang, Jiaqi Peng, Benyuan Cheng, Yueting Tan, Chunyan Tang, Hu ge, Bolong Liu, Yan Yu Published: 2026 ABSTRACT Male reproductive tract infections (MRTIs) are associated with serious clinical complications; however, their epidemiological characteristics remain insufficiently defined due to limitations in conventional diagnostic methods. This study utilized targeted next-generation sequencing (tNGS) to characterize the pathogen spectrum of MRTIs I n Hunan Province, China. Urethral swab specimens were collected from 594 male patients between February 2024 and January 2025. A tNGS panel targeting 61 pathogens was applied for pathogen detection. Statistical analyses were conducted using SPSS version 25.0. Of the 594 male reproductive tract swab samples analyzed, 484 (81.5%) were positive for at least one pathogen. Among the reported positive male samples, the highest positivity rate was observed in the 15–19-year age group (92.7%), followed by a gradual decline with age and a subsequent increase to 59.8% in individuals aged 40–49 years. The most prevalent bacterial pathogens were Ureaplasma parvum (29.5%), Ureaplasma urealyticum (23.3%), and Streptococcus agalactiae (23.3%). Subtype analysis of Ureaplasma parvum identified Ureaplasma parvum serovar 6 as the predominant subtype (11.4%), whereas Ureaplasma parvum serovar 14 was the least prevalent (0.6%). Other frequently detected pathogens included Candida albicans (7.2%) and Herpes simplex virus type 2 (3.3%). Among sexually transmitted pathogens, positivity rates were 5.2% for Neisseria gonorrhoeae and 0.8% for Treponema pallidum. High-risk Human papillomavirus infections were mainly attributable to Human papillomavirus 52 (19.2%) and Human papillomavirus 58 (8.7%). Co-infections were identified in 329 cases (68.0%), most commonly involving Streptococcus agalactiae (29.5%), Ureaplasma urealyticum (27.1%), Mycoplasma hominis (15.8%), and Human papillomavirus 52 (24.9%) or Human papillomavirus 58 (12.5%). Among HPV52-positive cases (n = 82), multi-subtype HPV co-infections most frequently involved HPV58 (25.6%), Human papillomavirus 53 (17.1%), and Human papillomavirus 51 (11.0%). In addition, bacterial co-infections in Human papillomavirus 53-positive samples were commonly associated with Ureaplasma urealyticum (23.2%), Streptococcus agalactiae (17.1%), and Ureaplasma parvum serovar 6 (12.2%). The tNGS-based analysis demonstrates a high burden of Human papillomavirus and Ureaplasma infections among men in Hunan Province, accompanied by complex co-infection patterns. The observed age-specific distribution of pathogens underscores the need for tailored prevention and control strategies.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-026-53598-x. Introduction The male reproductive tract consists of both external (penis and scrotum) and internal components, including the testes, epididymis, accessory glands, vas deferens, and urethra1. It represents a primary target for a wide range of pathogenic infections. Common pathogens include Ureaplasma urealyticum (U. urealyticum), Streptococcus agalactiae (S. agalactiae), Mycoplasma hominis (M. hominis), Herpesviruses, and sexually transmitted agents such as Treponema pallidum (T. pallidum). Neisseria gonorrhoeae (N. gonorrhoeae), Human immunodeficiency virus (HIV), and Human papillomavirus (HPV)2–7. Infections caused by these pathogens can lead to severe consequences for affected individuals, their offspring, and the broader population. Such adverse outcomes range from male infertility and malignancies of the reproductive tract to vertical transmission resulting in embryonic infection or fetal developmental abnormalities8. Reproductive system infections are recognized as significant risk factors for the development of male genital cancers9. According to the latest data released by the International Agency for Research on Cancer (IARC) of the World Health Organization, approximately 69,400 cases of male reproductive system cancers worldwide are attributable to HPV infection, including penile, oropharyngeal, and anal cancers10. Recent epidemiological studies indicate that the overall prevalence of genital HPV infection among men is approximately 31%, with High-risk Human papillomavirus (HR-HPV) types accounting for 21% of cases9. Notably, the highest positivity rates are observed in men aged 25–29 years. These findings highlight the critical need to incorporate male HPV infection into comprehensive prevention and control strategies aimed at reducing the incidence and mortality of HPV-associated diseases in men. Despite these serious implications, the male reproductive tract has received relatively limited attention in infectious disease research. This oversight is partly attributable to its restricted exposure to the external environment and its non-classical barrier tissue architecture1, which has contributed to an underestimation of its susceptibility to pathogenic invasion. In practice, the natural repair processes of the glans penis and foreskin following infection, as well as the desquamation of infected epithelial cells, occur relatively slowly in males11. This delayed epithelial turnover reduces the efficiency of pathogen clearance12. Moreover, the penile urethra serves as the primary entry site for most pathogens. Once local immune surveillance is bypassed, pathogens may ascend and spread to deeper reproductive structures. The testes, in particular, constitute a classic immune-privileged site in which systemic immune responses are inherently suppressed13. While this immunological environment is essential for protecting spermatogenesis from autoimmune damage, it may also facilitate pathogen persistence, thereby promoting chronic or latent infections13–15. Consequently, accurate pathogen identification, together with timely diagnosis and appropriate treatment, is critical for the effective management of male reproductive tract infections. At present, commonly used clinical diagnostic approaches often lack the capability to simultaneously detect a broad spectrum of pathogens. To comprehensively assess infection risks within the male reproductive system, a single multiplex assay capable of identifying multiple pathogens is highly advantageous, as it enables precise diagnosis and supports individualized therapeutic decision-making. Targeted next-generation sequencing (tNGS) integrates multiplex PCR or probe-based target enrichment with high-throughput sequencing, allowing for the simultaneous detection of dozens to thousands of known microbial pathogens within a single sample. This approach supports both DNA and RNA workflows, significantly shortens turnaround time, and offers high cost-effectiveness and flexibility. Although tNGS detects fewer pathogens than metagenomic next-generation sequencing (mNGS), it provides distinct advantages in terms of affordability and diagnostic efficiency. Importantly, previous studies have demonstrated that the diagnostic performance of tNGS is comparable to that of mNGS for microbial detection16–20. The present study aims to characterize the epidemiological profile of male reproductive tract pathogens in Hunan Province, thereby elucidating region-specific infection patterns and informing more precise diagnostic and preventive strategies. Methods Data source and research object The data were derived from a pathogen detection project targeting male reproductive tract infections conducted in Hunan between February 2024 and January 2025. Urethral swab samples were collected from male patients who sought medical attention for various reasons, including genital herpes, dyspareunia, erectile dysfunction, urethritis, and HPV infection. Inclusion criteria were defined as follows: (1) male patients with no history of anti-inflammatory medication use within the preceding two weeks; and (2) males presenting with genitourinary tract infection symptoms. Exclusion criteria comprised: (1) individuals with incomplete clinical documentation; and (2) those with chronic systemic conditions requiring prolonged pharmacotherapy. This study was approved by the Ethics Committee of Guangzhou Kingmed Medical Laboratory Center (Approval No. 2025036), and all procedures were conducted in strict accordance with the Declaration of Helsinki. Targeted next-generation sequencing Sample preparation To ensure optimal sample collection, subjects should be instructed to refrain from urinating for at least 1 h prior to sampling. Subsequently, a disposable flocking sampling swab should be gently inserted 2–4 cm into the male urethra to collect epithelial cells and secretions through rotational contact with the mucosal surface. The sampling tube was vortexed for 30 s to ensure thorough homogenization. Subsequently, 1.3mL of the specimen was transferred into a 1.5 mL sterile microcentrifuge tube, followed by the addition of an exogenous internal control, which was then mixed thoroughly. Pathogen enrichment was performed via high-speed centrifugation at 12,000 rpm for 5 min. After discarding the supernatant, 500µL of the sample was transferred into a bead-beating tube preloaded with 50µL of SDS for mechanical lysis. Following cell disruption, the sample was centrifuged again under the same conditions, and 250µL of the supernatant was collected for subsequent nucleic acid extraction. Positive and negative control groups were established using a commercial genital tract pathogen detection kit (KS637-SZD50-96, KingCreate, Guangzhou, China). Nucleic acid extraction Nucleic acids were automatically extracted using a dedicated extraction or purification reagent kit (KS118-BYTQ-96, KingCreate, Guangzhou, China) operated on the KingFisher Flex automated nucleic acid extraction platform (Thermo Scientific, Massachusetts, USA). Library construction and sequencing The Equalbit DNA HS Assay Kit was used to quantify nucleic acid concentrations, after which a defined volume was added to the multiplex PCR premix. Positive, negative, and no-template controls were simultaneously included. Target region enrichment PCR was performed per the manufacturer’s instructions, using sample nucleic acids as templates to selectively amplify pathogen sequences. PCR products were purified via magnetic bead-based methods. Library preparation followed the protocol of the tNGS Library Premix Kit (KS646-tNGSJT, KingCreate, Guangzhou, China), employing primers with sequencing adaptors and unique barcodes. After amplification, libraries were purified again using magnetic beads. The Qubit 3.0 fluorometer (Thermo Scientific, Massachusetts, USA) was used to determine optimal loading concentrations. Libraries were pooled at equal mass (20–60ng). Library quality was assessed by analyzing fragment size distribution using the Standard Cartridge Kit (S2, Houzebio, Hangzhou, China) and the Qsep100 nucleic acid analyzer (Bioptic, Taiwan, China), with final fragment sizes ranging from 250 to 350 bp. Bioinformatics analysis Sequencing data were processed using the Data Management and Analysis System (version 3.7.2, KingCreate). Quality control criteria included a Q30 score of ≥ 75%, a minimum of 50,000 raw reads per sample, and at least 50 normalized reads for internal reference amplification. Results interpretation The key interpretation metrics were Reads Per Kilobase (RPK), amplicon coverage, and amplicon quality control. (i)For amplicon coverage ≤ 0.4: RPK < 10 was classified as “excluded”; 10 ≤ RPK ≤ 300 as “low-positive”; RPK > 300 as “positive”. For amplicon coverage > 0.4: RPK < 10 as “excluded”; 10 ≤ RPK ≤ 200 as “low-positive”; RPK > 200 as “positive”.(ii)Amplicon quality control was defined by the alignment concordance rate between the maximum proportion of reads and the tNGS database, with values closer to 1 indicating higher quality. (i)For amplicon coverage ≤ 0.4: RPK < 10 was classified as “excluded”; 10 ≤ RPK ≤ 300 as “low-positive”; RPK > 300 as “positive”. For amplicon coverage > 0.4: RPK < 10 as “excluded”; 10 ≤ RPK ≤ 200 as “low-positive”; RPK > 200 as “positive”. For amplicon coverage ≤ 0.4: RPK < 10 was classified as “excluded”; 10 ≤ RPK ≤ 300 as “low-positive”; RPK > 300 as “positive”. For amplicon coverage > 0.4: RPK < 10 as “excluded”; 10 ≤ RPK ≤ 200 as “low-positive”; RPK > 200 as “positive”. (ii)Amplicon quality control was defined by the alignment concordance rate between the maximum proportion of reads and the tNGS database, with values closer to 1 indicating higher quality. Amplicon quality control was defined by the alignment concordance rate between the maximum proportion of reads and the tNGS database, with values closer to 1 indicating higher quality. Based on automated bioinformatics analysis, two senior clinicians specializing in reproductive tract infections and one clinical laboratory expert independently evaluated the data to determine reportable pathogens. Discrepancies were resolved through further assessment by senior clinical microbiologists21. tNGS detection range A total of 61 pathogen types were identified, including 12 bacteria, 6 fungi, 38 human papillomaviruses, 4 other viruses, and 1 parasite. The pathogen types and acronyms are shown in Table 1.Table 1Pathogens and abbreviations.PathogensAbbreviationsStreptococcusagalactiaeS. agalactiaeNeisseriagonorrhoeaeN. gonorrhoeaeHemophilusducreyiH. ducreyiMycoplasmahominisM. hominisChlamydiatrachomatisC. trachomatisMycoplasmagenitaliumM. genitaliumUreaplasmaurealyticumU. urealyticumTreponemapallidumT. pallidumUreaplasma parvum serovar 1U. parvum serovar 1Ureaplasma parvum serovar 3U. parvum serovar 3Ureaplasma parvum serovar 6U. parvum serovar 6Ureaplasma parvum serovar 14U. parvum serovar 14CandidaalbicansC. albicansCandidaglabrataC. glabrataCandidaparapsilosisC. parapsilosisCandidakruseiC. kruseiCandidatropicalisC. tropicalisCandidadubliniensisC. dubliniensisTrichomonas vaginalisT. vaginalisHerpes simplex virus type 1HSV-1Herpes simplex virus type 2HSV-2Varicella-zoster virusVZVCytomegalovirusCMVHuman papillomavirusHPV Table 1Pathogens and abbreviations.PathogensAbbreviationsStreptococcusagalactiaeS. agalactiaeNeisseriagonorrhoeaeN. gonorrhoeaeHemophilusducreyiH. ducreyiMycoplasmahominisM. hominisChlamydiatrachomatisC. trachomatisMycoplasmagenitaliumM. genitaliumUreaplasmaurealyticumU. urealyticumTreponemapallidumT. pallidumUreaplasma parvum serovar 1U. parvum serovar 1Ureaplasma parvum serovar 3U. parvum serovar 3Ureaplasma parvum serovar 6U. parvum serovar 6Ureaplasma parvum serovar 14U. parvum serovar 14CandidaalbicansC. albicansCandidaglabrataC. glabrataCandidaparapsilosisC. parapsilosisCandidakruseiC. kruseiCandidatropicalisC. tropicalisCandidadubliniensisC. dubliniensisTrichomonas vaginalisT. vaginalisHerpes simplex virus type 1HSV-1Herpes simplex virus type 2HSV-2Varicella-zoster virusVZVCytomegalovirusCMVHuman papillomavirusHPV Pathogens and abbreviations. Statistical analyses Raw sequencing reads were normalized to reads per million (RPM) to standardize sequencing depth. Descriptive statistics included infection rate calculations (proportions with 95% confidence intervals) and age-stratified prevalence visualization via segmented bar plots. Continuous variables were presented as mean (95% CI) or median (interquartile range, IQR), and categorical variables were presented as numbers (%). Comparisons between different groups were conducted by the χ² test or Fisher’s exact test. Statistical analyses were performed using SPSS version 25.0 (IBM, Chicago, IL, USA). Multivariate logistic regression model was used to evaluate the association between pathogen infection and co-infection status. The outcome variable was the infection status of each pathogen (positive = 1, negative = 0), the main independent variable was the co-infection status (presence = 1, no = 0), and the age group was adjusted as a covariate. The multivariable logistic regression aimed to explore whether co-infection status (defined as ≥ 2 pathogens detected) influenced the risk of individual pathogen detection, adjusting for age as a potential confounder. This approach was motivated by prior evidence suggesting that co-infections may alter host susceptibility to specific pathogens. R software (R v4.3.1) was used to calculate the aOR value and 95% confidence interval, and the statistical significance was set to P < 0.05. Results and analysis Sample characteristics and positive rates Among 594 analyzed samples, 484 tested positive for pathogens, yielding a positivity rate of 81.48% (Fig. 1A). Positive cases were stratified into simple infections (single pathogen) and mixed infections (≥ 2 pathogens), accounting for 32.02% and 67.98% of cases, respectively (Fig. 1B). The distribution of co-infection complexity was as follows: dual infections (117, 35.56%), triple infections (69, 20.97%), quadruple infections (52, 15.81%), quintuple infections (34, 10.33%), sextuple infections (17, 5.17%), septuple infections (15, 4.56%), and octuple infections (8, 2.42%). Fig. 1Characteristics and positive rates. (A) Positive rates and negative rates. (B) Single infection and mixed infection. (C) Positive rates by age group. Characteristics and positive rates. (A) Positive rates and negative rates. (B) Single infection and mixed infection. (C) Positive rates by age group. tNGS was used for microbial pathogen identification. All 594 cases were included in the analysis, with a median age of 31 years (interquartile range [IQR]: 24–46 years). The prevalence of reproductive tract pathogens did not differ significantly among age groups (χ² = 4.82, p = 0.436). Nevertheless, the highest positivity rate was observed in the 15–19-year age group (89.09%), whereas the lowest rate occurred in individuals aged 30–39 years (77.04%) (Fig. 1C). Pathogen infection spectrum In the study population, the top five pathogens with the highest positive rate were High-risk human papillomavirus (HR-HPV, 429/594, 72.22%), Low-risk human papillomavirus (LR-HPV, 374/594, 62.96%), U. parvum (143/594, 24.07%), S. agalactiae (113/594, 19.02%), U. urealyticum (113/594, 19.02%). Pathogen-specific positivity rates were systematically analyzed among pathogen-positive individuals (Fig. 2A). S. agalactiae and U. urealyticum demonstrated significantly higher prevalence rates than other pathogens, reaching 23.35% (113/484). Among atypical pathogens, M. hominis and C. trachomatis exhibited prevalence rates of 11.16% (54/484) and 10.95% (53/484), respectively. In contrast, C. species, Herpesviruses, and T. vaginalis showed comparatively lower positivity rates. Among these pathogens, C.albicans (35/484, 7.23%) and HSV-2 (16/484, 3.31%) were the most frequently detected (Fig. 2A). The positive rates of HR-HPV and LR-HPV were 88.64% (429/484) and 77.27% (374/484), respectively. Among HPV, HPV52 (93/484, 19.22%), HPV6 (73/484, 15.08%), and HPV58 (42/484, 8.68%) exhibited the highest positivity rates. Notably, HPV68—a potentially carcinogenic genotype routinely included in HPV screening panels—displayed marked subtype heterogeneity, with HPV68b (17/484, 3.51%) occurring significantly more frequently than HPV68a (1/484, 0.21%). Overall, HPV68 was detected in 18 samples, with HPV68b representing the predominant subtype (Fig. 2B). Fig. 2The positive rates and co-infection of each pathogen. (A) Positive rates for bacteria, fungi, and other viruses (except HPV). (B) The detction of HR-HPV and LR-HPV was analyzed in the histogram. (C-D) Mixed infection of bacteria, fungi and other viruses. (E) The specific situation of co-infection of key pathogens (HPV58, HPV52, C. albicans, M. hominis, U. urealyticum, S. agalactiae) and other pathogens. The positive rates and co-infection of each pathogen. (A) Positive rates for bacteria, fungi, and other viruses (except HPV). (B) The detction of HR-HPV and LR-HPV was analyzed in the histogram. (C-D) Mixed infection of bacteria, fungi and other viruses. (E) The specific situation of co-infection of key pathogens (HPV58, HPV52, C. albicans, M. hominis, U. urealyticum, S. agalactiae) and other pathogens. Mixed infections accounted for a substantial proportion of positive cases (329/484, 67.98%). High mixed-infection rates were observed for S. agalactiae (97/329, 29.48%), M. hominis (52/329, 15.81%), C.tropicalis (45/329, 13.68%), U. urealyticum (89/329, 27.05%), U. parvum serovar 3 (38/329, 11.55%), and U. parvum serovar 6 (50/329, 15.20%), all exceeding 10% (Fig. 2C). Among HR-HPV subtypes, HPV52 (82/329, 24.92%) and HPV58 (41/329, 12.46%) exhibited the highest co-infection rates, whereas HPV68a showed the lowest co-infection frequency (1/329, 0.30%). For LR-HPV subtypes, HPV6 (60/329, 18.24%) demonstrated the most frequent co-infection pattern. All HPV subtypes were detectable in mixed-infection samples (Fig. 2D). GBS demonstrated preferential co-infection patterns with C. trachomatis (11/97, 11.34%), M. hominis (6/97, 6.19%), HPV52 (12/97, 12.37%), and HPV59 (11/97, 11.34%). Furthermore, U. urealyticum exhibited distinct co-infection associations, predominantly with S. agalactiae (32/89, 35.96%), M. hominis (23/89, 25.84%), C. trachomatis (13/89, 14.61%), and HPV52 (18/89, 20.22%) (Fig. 2E). The four U. parvum subtypes exhibited comparable frequencies in mixed infections. Notably, U. parvum serovar 6 was significantly overrepresented in co-infections involving M. hominis or HPV58, whereas U. parvum serovar 3 showed a marked increase in prevalence in cases co-infected with C. albicans (Fig. 2E). Age-specific pathogen prevalence and temporal trends Distinct age-related variations in pathogen prevalence were observed across different age groups. U. urealyticum and U. parvum exhibited comparable positivity rates across all age cohorts, with no statistically significant differences (p > 0.05) (Fig. 3A). S. agalactiae infections were detected in all age groups and showed the highest prevalence in males aged 30–39 years. However, intergroup differences did not reach statistical significance (Fig. 3A). Fig. 3Trends in pathogen infection by age group. (A) Comparison of the positive rates of various pathogens among patients of different age groups. (B) Detection of bacteria, fungi and other viruses at different ages. (C) The proportion of U. parvum subtypes in each age group. Trends in pathogen infection by age group. (A) Comparison of the positive rates of various pathogens among patients of different age groups. (B) Detection of bacteria, fungi and other viruses at different ages. (C) The proportion of U. parvum subtypes in each age group. Notably, C. trachomatis, N. gonorrhoeae, and C. albicans infections exhibited a predilection for younger populations. C. trachomatis positive rates demonstrated a progressive decline with advancing age (Fig. 3A-B). The highest N. gonorrhoeae prevalence was identified in males aged 15–19 years, followed by a continuous reduction post-25 years (p < 0.001) (Fig. 3A-B). Although C. albicans infections showed a decreasing trend with age, no significant intergroup differences were detected. Other pathogens exhibited relatively low prevalence rates across all age groups (Fig. 3A-B). These findings highlight distinct age-specific patterns in pathogen distribution, particularly emphasizing the elevated susceptibility of younger males to N. gonorrhoeae infections. Further analysis of U. parvum subtypes across age groups revealed distinct epidemiological trends. The prevalence of U. parvum serovar 3 progressively declined with age, reaching its lowest level in the 30–39-year group, followed by a slight increase in individuals aged 40–49 years. This decline in U. parvum serovar 3 was accompanied by a reciprocal increase in U. parvum serovar 6 prior to the 30–39-year age group (Fig. 3C). In addition, U. parvum serovar 14 was exclusively detected in individuals aged 25–49 years, with no positive cases observed in those aged 15–24 years or ≥ 50 years. Analysis of age-specific trends in HR-HPV positivity revealed relatively consistent patterns among individuals younger than 29 years. Across all age groups, the prevalence of HPV16 remained stable, whereas HPV52 and HPV58 exhibited a characteristic U-shaped distribution (Fig. 3C). We employed a multivariable logistic regression model to assess the association between pathogen infections and co-infection status. Some pathogens were significantly associated with co-infection, with infections of HPV58, HPV51, and M. hominis significantly increasing the risk of genital tract co-infections in male patients. The probabilities of co-infection among infected males were 35.66 times, 29.72 times, and 24.70 times higher than those in uninfected males, respectively (Supplementary materials). Disscussion Although tNGS can effectively detect pathogen nucleic acids, this does not equate to clinical infection. Pathogens may exist within the host without causing symptoms or associated diseases, whereas true infection implies that the pathogen actively contributes to disease onset and progression. Distinguishing colonization from true infection requires integration with additional clinical evidence. In this study, tNGS analysis of 594 male urethral swab samples collected in Hunan Province between February 2024 and January 2025 revealed an overall pathogen positivity rate of 81.48%, with mixed infections accounting for 67.98% of positive cases. HR-HPV and LR-HPV dominated the pathogen spectrum, with HPV52 (19.22%) identified as the most prevalent HR-HPV subtype. These findings are consistent with multiple population-based studies conducted in China. For example, a study from Beijing reported HPV52, HPV58, HPV16, HPV51, and HPV66 as the most prevalent genotypes among males, with HPV52 and HPV58 constituting the most common co-infection pattern22. Similarly, investigations in southern China identified HPV58, HPV52, and HPV16 as the dominant genotypes in male populations23. Comparable genotype distributions have also been reported in female genital tract infections in China, where HPV16, HPV52, and HPV58 represent the principal oncogenic types24. Although HPV16 and HPV18 remain the most prevalent genotypes worldwide9, epidemiological patterns in Asian populations exhibit higher prevalence of HPV52 and HPV58 infections. These regional variations underscore the necessity for developing tailored HPV vaccines targeting genotype-specific distributions across different geographical populations. HPV6 (15.08%), the most prevalent non-HR-HPV subtype, aligned with global epidemiological trends. Moreover, HPV52 and HPV58 exhibited a “U-shaped” age distribution, with higher rates in younger (< 29 years) and older (≥ 50 years) populations, mirroring patterns observed in cervical HPV studies25,26. Among mixed-infection cases, at least one HPV subtype was detected in 78.72% of cases. U. parvum (29.55%) and S. agalactiae (23.34%) were also highly prevalent, reflecting their roles in urethritis and ascending infections. Notably, male reproductive tract pathogens exhibited persistently high positive rates across all age groups. Parvoplasma has a high prevalence. U. parvum is more prevalent and frequently detected in asymptomatic males compared to U. urealyticum, with the latter often existing as a commensal organism in healthy populations. This oversight may explain why early studies failed to differentiate between U. urealyticum and U. parvum. However, emerging evidence implicates U. parvum in male infertility, demonstrating its adverse clinical impact. In infertile males, the prevalence of U. parvum exceeds that of U. urealyticum, with U. parvum serovar 3 and U. parvum serovar 14 exhibiting stronger associations with urogenital disorders and subfertility compared to other subtypes27. Our findings revealed that U. parvum serovar 14 was exclusively detected in individuals aged 25–49 years, while being nearly absent in younger populations. Furthermore, an age-dependent shift was observed where U. parvum serovar 3 infections gradually transitioned to U. parvum serovar 6 dominance, peaking in the 30–39 year age group, suggesting a region-specific infection pattern. In contrast, low positive rates of T. vaginalis and HSV-2 may reflect regional epidemiological patterns or sampling biases. Moreover, U. urealyticum and S. agalactiae showed a high positive rate in this study, which emphasized the clinical significance of opportunistic pathogens in male genital tract infection. The transition from colonization to pathogenicity depends on host-microorganism interactions and microecological disorders, such as mucosal barrier destruction, immunosuppression, or co-infection of multiple pathogens. U. urealyticum can lead to male infertility through different mechanisms, change sperm morphology, forward movement, total movement ability and survival rate, and reduce fertility28–30. However, due to the lack of clinical symptom stratification, its role as a colonizing organism versus a true infectious pathogen remains unclear in this study. As an asymptomatic infection member of the gastrointestinal tract and reproductive tract, S. agalactiae can still improve its pathogenic potential by adhering to reproductive tract epithelial cells, inhibiting immune activation, and enhancing the ability to cross the host barrier31. Co-infection is also one of the ways in which S. agalactiae destroys the microecological balance. For example, co-infection with C.albicans weakens the host T cell-mediated immune response32. In this study, the lack of control samples in asymptomatic healthy people limits us to clearly distinguish between pathogenesis and colonization. However, the high co-infection rate hints at potential interactions between opportunistic and obligate pathogens (such as HR-HPV, C. trachomatis), though their clinical impact requires validation through longitudinal studies correlating pathogen combinations with disease outcomes. T. pallidum, a major pathogen responsible for sexually transmitted infections, was detected in only 4 samples in this study, demonstrating a notably low positive rates. Due to the limited number of positive cases, the current data cannot conclusively delineate its epidemiological patterns or clinical characteristics. Notably, systematic investigations by Nieuwenburg et al. have confirmed that urine samples exhibit significant diagnostic sensitivity for T. pallidum detection during early-stage infections, including primary, secondary, and early latent syphilis33. Furthermore, recent work by Wang et al. revealed that the DNA load of T. pallidum in urinary sediment substantially exceeds that in plasma or urine supernatant34. These findings provide critical molecular evidence for overcoming the limitations of serological window periods and advancing early infection diagnosis. To comprehensively evaluate the clinical utility of tNGS in syphilis screening, future studies should prioritize large-scale cohort analyses and multicenter clinical validations to rigorously assess its diagnostic accuracy and implementation potential. Among the viruses in the detection range, HSV-2 had the highest positive rates. HSV-1 and HSV-2 serve as the primary etiologic agents of genital herpes, with epidemiological studies indicating approximately 70% of infected individuals maintain asymptomatic latent infection35. Pathogen detection data from symptomatic male patients in Hunan Province revealed a significantly higher positivity rate for HSV-2 compared to HSV-1 (ratio 3:1), demonstrating a bimodal age distribution predominantly clustered in adolescents aged 15–19 years and older adults ≥ 50 years. HSV-1 demonstrates a notably higher positive rate in the 20–24 age group, with prevalence progressively declining with advancing age (Fig. 3A). Studies demonstrate that primary genital HSV-2 infection exhibits a median recurrence rate of 5 episodes in the first year, compared to 1 episode for HSV-1, indicating higher reactivation frequency of HSV-2 than HSV-1 over time36. Recurrence rates represent a potential determinant underlying the age-specific disparities between HSV-1 and HSV-2 infection profiles. In this study, CMV is the virus with the second highest positive rate, which can be infected in all age groups without obvious epidemiological characteristics. Notably, CMV infection impairs sperm maturation, reduces motility, and causes pathological damage, contributing significantly to male infertility37–39. However, existing studies have not established definitive correlations between CMV infection and other male reproductive tract diseases, nor have they elucidated the pathological mechanisms underlying disease development associated with CMV co-infections. Among the fungi in the study, the positive rate of C.albicans was the highest. C.albicans is often used as a pathogenic bacterium in the female genital tract, and the incidence of genital candidiasis during pregnancy is extremely high40. C.albicans is also the most common pathogen causing balanoposthitis41. A small number of early studies have reported that C.albicans has a negative impact on sperm function by reducing sperm motility and promoting apoptosis42,43. Compared with other studies, in our study, the HR-HPV positive rate of reproductive tract infection positive male population reached 72.22%, and the LR-HPV detection rate reached 69.96%, which was significantly higher than the international reported data. We believe that this difference is mainly due to the essential difference in detection techniques: (1) tNGS independently amplified tens of thousands of target sequences through multiple PCR reactions, which reduced the detection limit to 50–450 CFU/mL18. Compared with traditional microbiological detection, the detection sensitivity of tNGS can reach 94.7%18, especially good at identifying low viral load infections (such as latent HPV infection) and multiple co-infection status. (2) the detection system used in this study covered 61 pathogens, of which HPV typing detection was extended to 38 subtypes (including 19 h-HPV), which significantly broadened the detection spectrum compared with conventional clinical detection (usually covering 6–15 subtypes). Moreover, during subclinical or latent infection stages, HPV DNA may persist at low viral loads and retain the potential for reactivation under specific conditions44–47. The elevated HPV positivity rates observed in this study likely reflect the high sensitivity of tNGS, which enables detection of low-load infections or latent states undetectable by conventional methods, rather than necessarily being linked to clinically overt infections. Consistent with previous studies, U. parvum serovar 6 is predominant among infertile males48. However, for the first time, we report that U. parvum serovar 6 exhibits the highest positive rate in symptomatic males from Hunan Province: U. parvum serovar 3 dominates in younger males (15–29 years), while U. parvum serovar 6 infection significantly increases in the 30–39 year-old cohort. Moreover, most current studies focus on single-pathogen infections, neglecting the potential harm of co-infections. Our findings reveal frequent co-detection of HR-HPV (HPV52) with bacterial pathogens (U. parvum and S. agalactiae). HPV co-infection with bacterial pathogens could theoretically disrupt mucosal barriers, as observed in female populations, though this hypothesis remains to be tested in male cohorts. In other male populations with reproductive tract diseases, for instance, co-infection rates of HPV and U. parvum reach 34.5% in infertile males, accompanied by significantly reduced sperm motility49, while HPV and C. trachomatis co-infection rates soar to 28.7% in symptomatic prostatitis patients50. The observed variability in HPV-bacterial co-infection patterns can be attributed to differences in study population disease profiles, geographical disparities, and detection methodologies. It should be noted that this study has several limitations. Firstly, the combination of high outpatient volume and brief consultation periods posed challenges in establishing definitive diagnoses, compounded by the exclusive inclusion of symptomatic individuals with heterogeneous reproductive tract manifestations that hindered clear subgroup stratification. Secondly, the investigation did not account for behavioral and socioeconomic confounding factors including sexual practices, contraceptive utilization, and healthcare accessibility, which may influence pathogen transmission dynamics and age-specific distribution patterns. Thirdly, the small sample size of some subgroups (such as 15–19 years old and 25–29 years old) and the high aggregation of pathogen co-infections (such as S. agalactiae and U. urealyticum) led to the failure of this study to obtain meaningful multivariate statistical results. S. agalactiae (aOR = 6.66, p = 3.8 × 10− 11) and HPV52 (aOR = 7.56, p = 1.7 × 10− 9) were the most prominent. Whether there is a synergistic effect between these two pathogens in co-infection is worthy of further study. The significant high aOR values of high-risk HPV (such as HPV16, HPV58, HPV51) further support the core position of HPV in multiple infections, which may be related to the increased risk of secondary infection after host immunosuppression or mucosal injury. The significant association of C. albicans suggests the complexity of fungal and bacterial/viral co-infection. The high co-infection rates suggest a potential synergy between opportunistic and obligate pathogens in disease progression, though this hypothesis requires validation through longitudinal studies correlating pathogen load with clinical outcomes. A key limitation is the absence of asymptomatic controls, which precludes definitive conclusions on whether detected pathogens represent colonization or true infection. Future studies should integrate clinical symptom scoring with tNGS data to clarify pathogenic contributions and validate the clinical utility of tNGS across diverse populations, thereby optimizing its diagnostic performance in clinical practice. Conclusion This study presents the first comprehensive tNGS-based analysis of male reproductive tract infections in Hunan Province. The enhanced diagnostic performance of tNGS overcomes key limitations of conventional methods by enabling the timely and accurate identification of mixed infections. The identified age-specific pathogen distributions, together with insights into complex co-infection patterns, underscore the need for integrated public health strategies, including targeted HPV vaccination programs and strengthened antimicrobial stewardship. Future studies should investigate the longitudinal clinical outcomes of co-infections and further validate the clinical applicability of tNGS across diverse populations to maximize its diagnostic and preventive value. Supplementary Information Below is the link to the electronic supplementary material. Supplementary Material 1 Supplementary Material 1